Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MANTICO 2: Evusheld and Paxlovid vs Sotrovimab in Mild/Moderate COVID-19
NCT05321394Phase 3Completed
- Sponsor
- Azienda Ospedaliera Universitaria Integrata Verona
- Start
- Mar 2022
- Primary completion
- Oct 2023
- Modality
- Monoclonal Antibodies, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of tixagevimab + cilgavimab, Nirmatrelvir in coronavirus disease 2019 (COVID-19), sponsored by Azienda Ospedaliera Universitaria Integrata Verona. Started Mar 2022; status: completed.
02
Drugs
tixagevimab + cilgavimabNirmatrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05321394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05321394.